Sickle Cell Disease (SCD) - Market Insight, Epidemiology and Market Forecast -2027

DelveInsight Business Research LLP


Albany, NY -- (SBWIRE) -- 10/26/2018 -- DelveInsight has announced the addition of the "Sickle Cell Disease (SCD) - Market Insight, Epidemiology and Market Forecast -2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of Sickle Cell Disease for the six major markets i.e., the United States and EU5 (France, Germany, Italy, Spain, UK). The Report covers the overview, treatment practice and Sickle Cell Disease forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

Sickle Cell disease, also known as sickle cell anaemia, includes a group of disorders affecting the red blood cells in the body. It is an inherited blood disorder characterized by defective haemoglobin. Sickle cell anaemia is a condition in which there aren't enough healthy red blood cells to carry adequate oxygen throughout the body. Changes in conditions where red blood cells behave differently such as dehydration, low oxygen levels and elevated temperature may cause red blood cells to block the small blood vessels, restricting blood flow. Sickle cell disease is irreversible, an untreatable health problem which affects males and females equally, and is responsible for increased morbidity and mortality in affected persons.

There were approximately 132,000 prevalent cases of Sickle Cell Disease in 2016 in the 7MM. According to DelveInsight, it is estimated that the prevalent cases are expected to increase by 2027. As per DelveInsight, the United States accounts for the highest prevalent population of Sickle Cell Disease due to a large number of immigrants from African countries per year, followed by the EU5. Among the European countries, France has the highest prevalent population of Sickle Cell Disease with ~15,000 cases followed by the United Kingdom which has a prevalent population of ~13,000 in 2016. Spain has the lowest prevalent population. According to the KOL views, it was found that there is no prevalence of Sickle Cell Disease in Japan since this disease doesn't occur in the Japanese population.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies

1. GBT Therapeutics
2. Pfizer
3. Novartis
4. AstraZeneca
5. Ironwood Pharmaceuticals
6. Imara Therapeutics
And many others
Drugs covered

1. Crizanlizumab
2. GBT-440
And many others
Report Scope

The report covers a descriptive overview of the Sickle Cell Disease, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Sickle Cell Disease and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Sickle Cell Disease are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Sickle Cell Disease market is included in the report, covering drug outreach in 6 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Sickle Cell Disease market.